Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

Benzer Materyaller

• A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
  Yazar:: Correale, P, ve diğerleri
  Baskı/Yayın Bilgisi: (2004)
• FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
  Yazar:: Souglakos, J, ve diğerleri
  Baskı/Yayın Bilgisi: (2006)
• Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
  Yazar:: Fischel, J-L, ve diğerleri
  Baskı/Yayın Bilgisi: (2001)
• Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer
  Yazar:: Peinert, Stefan, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
  Yazar:: Zoetemelk, Marloes, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)